《2010年全球生物技术产业发展研究报告》(116页).rar Contents The　new　normal:　the　global　perspective 2　Global　introduction The　new　normal 7　Perspectives　for　the　new　normal Asset-centric　financing Francesco　De　Rubertis　and　Michèle　Ollier,　Index　Ventures 9　Perspectives　for　the　new　normal Lean　proof　of　concept Michael　Clayman,　Flexion　Therapeutics 12　A　closer　look Reforming　US　health　care Connie　Austin,　Ernst　＆　Young　LLP 14　Perspectives　for　the　new　normal Focus　and　leverage Edward　Lanphier,　Sangamo　BioSciences 16　Perspectives　for　the　new　normal Succeeding　together Leonard　Schleifer,　Regeneron　Pharmaceuticals 17　Perspectives　for　the　new　normal Efficiency　and　leverage John　Maraganore,　Alnylam　Pharmaceuticals 20　Perspectives　for　the　new　normal There＇s　gold　in　those　efficiencies Werner　Lanthaler,　Evotec　AG 21　Bioech　innovation　and　the　role　of　public　policy James　Greenwood,　Biotechnology　Industry　Organization 22　Using　FIPNet　to　supercharge　the　innovation　engine John　Lechleiter,　Eli　Lilly　and　Company New　opportunities:　country　profiles 26　Conversation　on　emerging　markets New　opportunities Kiran　Mazumdar-Shaw,　Biocon Canwen　Jiang,　Genzyme 30　China　year　in　review Accelerating　reforms 31　A　closer　look Providing　incentives　to　encourage　continuous　quality　improvement Cherrie　Che,　Ernst　＆　Young　Advisory　Services　Ltd 36　India　year　in　review Preparing　for　the　opportunities　ahead 39　Japan　year　in　review Rekindling　investment 41　A　closer　look Funding　innovation Yuji　Anzai,　Ernst　＆　Young　Shin　Nihon　LLC 43　Singapore　year　in　review Manufacturing　a　biopharmaceutical　hub 45　New　Zealand　year　in　review A　new　pragmatism 47　Brazil　year　in　review Fueling　the　future 50　Malaysia　year　in　review A　strategic　focus　on　biotech ....